Ayala Pharmaceuticals, Inc.

Industry

  • Pharmaceuticals
    • Vaccines
  • Biotechnology
    • Drug Discovery Technologies
      • Bioinformatics

Other Names/Subsidiaries

  • Biosight
See more in Biomedtracker

Latest on Ayala Pharmaceuticals, Inc.

Scrip

Deal Watch: Novo Nordisk, IMMvention To Partner On Sickle Cell Disease

 
• By Joseph Haas, Dexter Jie Yan, Xu Hu, and Vibha Ravi

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Novo Nordisk, IMMvention Collaboration

Scrip

Finance Watch: OS Therapies Raises $6.4m In Year’s 14th Biopharma IPO In The US

 
• By Mandy Jackson

OS Therapies Incorporated launched the 14th biopharmaceutical company initial public offering in the US in 2024 on 31 July, selling 1.6 million shares at $4 each to gross $6.4m in the smallest IPO so

Scrip

Deal Watch: Bristol To Link Up With VantAI On Molecular Glue Therapies

 
• By Joseph Haas

Scrip regularly covers business development and deal making in the biopharmaceutical industry. Deal Watch is supported by deal intelligence from Biomedtracker. Bristol, VantAI Pair Technologies In Pr

Scrip

Finance Watch: Biopharma Public Offerings Fell In Q4, But Activity Is Booming In Q1

 
• By Mandy Jackson

Biomedtracker’s latest report on biopharmaceutical company fundraising shows a 25.1% decline in year-over-year dollars raised, from $17.5bn in the fourth quarter of 2022 to $13.1bn in Q4 of 2023. Foll